

CURZA ANNOUNCES FORMATION OF BOARD OF ADVISORS & ANTIBIOTIC DEVELOPMENT TEAM

SALT LAKE CITY, Utah—March 1, 2017— Curza, is excited to welcome Dr. Lynn Silver, Dr. George Drusano, Dr. Michael Barbachyn, Dr. Paul Eckburg and Dr. Alexander Mankin to their Board of Advisors and as members of their antibiotic development team. These individuals are all experts in their various fields and have decades of experience in the infectious disease space. Their addition to Curza's team will dramatically help Curza achieve its goals of developing novel antibiotics.

Lynn Sliver. Lynn had a successful career at Merck (senior investigator) and at the National Institutes of Health (senior staff fellow) and discovered LPXC and INVANZ. Throughout her career, she has authored significant research papers and reviews in the field of bacterial genetics, physiology, biochemistry and the discovery and analysis of antibacterial agents. Lynn graduated from Brandeis University with a BA in Biology and from Tufts University School of Medicine with a PhD in Molecular and Microbiology.

George Drusano. George is the Director of the Institute for Therapeutic Innovation at the University of Florida and an active researcher focused on mathematical modeling and the pharmacodynamics of anti-infective chemotherapy, anti-tuberculosis agents, MDR/XDR nosocomial pathogens and multiple anti-viral agents. George is a reviewer for many prestigious peer-reviewed journals and is a Fellow at the Infectious Disease Society of America. George graduated magna cum laude from Boston College and graduated cum laude from the University of Maryland School of Medicine.

Michael Barbachyn. Mike currently serves as a professor and Brummel Chair in Organic Chemistry at Calvin College and has extensive experience in developing antibiotics and inventor of Zyvox. Mike served as Director of Infection Discovery for AstraZeneca, Director of Antibacterial Chemistry at Pfizer and Associate Director of Medicinal Chemistry at Pharmacia. Mike has a BA in Chemistry from Calvin College, a PhD in Organic Chemistry from Wayne State University and was an NIH Postdoctoral Fellow at Yale University.

Paul Eckburg. Paul has worked in the clinical research and anti-infective drug development space for over 17 years. Paul currently serves as an Infectious Disease consultant for Cerexa and has been involved in the development of multiple approved anti-infective drugs. Paul received a BS in Cell and Structural Biology from the University of Illinois at Urbana-Champaign, his M.D. from Rush University and completed his Internal Medicine residency and Infectious Disease fellowship at Stanford University School of Medicine, where he continues to serve as an Adjunct Clinical Assistant Professor.

About Curza— Curza is a Utah-based drug development company focused on developing novel therapeutics to combat antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and is backed by Clarke Capital Partners and other private investors. Visit www.curza.com for more information.

For media inquiries, please contact: Ryan Davies at rd@curza.com